medigraphic.com
Colegio de Medicina Interna de México.

2022, Number 5

<< Back Next >>

Med Int Mex 2022; 38 (5)

Extrapulmonary manifestations of COVID-19

Moreno-Madrigal LG, Hernández-Lima AE

Language: Spanish
References: 53
Page: 1025-1040
PDF size: 264.08 Kb.


ABSTRACT

Coronaviruses are a large family of single-stranded ARN viruses that infect a wide variety of animals, including humans. The SARS-CoV-2 virus, which is responsible for the disease called COVID-19, has infected 27,249,308 people and caused 890,971 deaths worldwide until September 7, 2020. Considering the genetic similarities between SARSCoV- 2 and the epidemic coronaviruses SARS-CoV and MERS, presumably they share tropisms for specific cell lines and systemic conditions. The clinical and paraclinical characteristics of this new virus have been described in detail at the pulmonary level, although there is increasing evidence that it is a multisystemic agent. In the present work, we describe the extrapulmonary manifestations of COVID-19 reported to date, including hematological, cardiovascular, neurological, renal, muscular, ophthalmological, endocrine-metabolic, gastrointestinal, hepatobiliary, cutaneous and in special populations: pediatric (including multisystemic inflammatory syndrome) and pregnant women. It is essential to know the systemic complications of SARS-CoV-2 infection when managing these patients, given the potential risk to life of the most serious manifestations. Therefore, it is advisable to consider them in a targeted manner and provide timely treatment as far as possible.


REFERENCES

  1. Osorio MF, Vaca RG. Extrapulmonary manifestations ofSARS-CoV-2. A Brief Review. Infect Dis Clin Pract 2020; 28(4): 196-199.

  2. Dong E, Du H, Gardner L. An interactive web-based dashboardto track COVID-19 in real time. Lancet Infect Dis2020; 20: 533-534. doi: 10.1016/S1473-3099(20)30120-1.

  3. Adhikari SP, Meng S, Wu YJ, Mao Y, Ye R, Wang QZ, et al.Epidemiology, causes, clinical manifestation and diagnosis,prevention and control of coronavirus disease (COVID-19)during the early outbreak period: a scoping review. InfectDis Poverty 2020; 9 (1): 29. doi: 10.1186/s40249-020-00646-x.

  4. Gupta A, Madhavan MV, Sehgal K, Nair N, Mahajan S,Sehrawat TS, et al. Extrapulmonary manifestations ofCOVID-19. Nature Medicine 2020; doi: 10.1038/s41591-020-0968-3.

  5. Góngora-Gómez O, Gámez-Leyva LR. Manifestacionesextrapulmonares de la infección por el nuevo coronavirusSARS-CoV-2. Rev Haban Cienc Méd 2020; 19 (Supl.):e3378.

  6. Terpos E, Ntanasis-Stathopoulos I, Elalamy I, Kastritis E,Sergentanis E, Politou M, et al. Hematological findingsand complications of COVID-19. Am J Hematol 2020; 95:834-847. doi: 10.1002/ajh.25829.

  7. Kim HR, Lee YE, Kang MG, Lee SY, Lee JH, Shin MG.Coronavirus disease-19 and its hematological manifestations.Blood Res 2020; 55 (2): 71-74. doi: 10.5045/br.2020.2020121.

  8. Klok FA, Kruip MJHA, van der Meer NJM, Arbous MS,Gommers DAMPJ, Kant KM, et al. Incidence of thromboticcomplications In critically ill ICU patients with COVID-19. Thromb Res 2020; 191: 145-147. doi: 10.1016/j.thromres.2020.04.013.

  9. Mucha SR, Dugar S, McCrae K, Joseph D, Bartholomew J,Sacha GL, Militello M. Coagulopathy in COVID-19: Manifestationsand management. Cleve Clin J Med 2020; 87 (8):461-468. doi: 10.3949/ccjm.87a.ccc024.

  10. Lima R, Cortinhas-Filho C, Ferreira-Filho CM, Vaisman M,Cossenza A, Pinto-Rebello C, et al. Hemophagocytic syndromeand COVID-19. Respir Med Case Rep 2020; 31:1-4.doi: 10.1016/j.rmcr.2020.101162.

  11. Xion TY, Redwood S, Prendergast B, Chen M. Coronavirusesand the cardiovascular system: acute and long-term implications.Eur Heart J 2020; 41: 1798-1800. doi: 10.1093/eurheartj/ehaa231.

  12. Figueroa-Triana JF, Salas-Márquez DA, Cabrera-Silva JS,Alvarado-Castro CC, Buitrago-Sandoval AF. COVID-19 yenfermedad cardiovascular. Rev Colomb Cardiol 2020; 27(3): 166-174.

  13. Clemente-Herrera A, Sánchez-De la Torre EJ, Enríquez-Contreras JM. Manifestaciones cardiológicas en pacientescon COVID-19. Med Int Méx 2020; 36 (3): 357-364.

  14. Marschall A, Concepción-Suárez R, Dejuan-Bitriá C,Fernández-Pascual MC. Pericarditis aguda secundaria aCOVID-19. Emergencias 2020; 32: 217-222.

  15. Mao L, Jin H, Wang M, Hu Y, Chen S, He Q, Hu Y, et al.Neurologic manifestations of hospitalized patients withcoronavirus disease 2019 in Wuhan, China. JAMA Neurol2020; 77 (6): 683-690. doi:10.1001/jamaneurol.2020.1127.

  16. Whittaker A, Anson M, Harky A. Neurological manifestationsof COVID-19: A systematic review and current update.Acta Neurol Scand 2020; 142: 14-22. doi: 10.1111/ane.13266.

  17. Ellul M, Benjamin L, Singh B, Lant S, Michael BD, EastonA, et al. Neurological Associations of COVID-19. Lancet2020; 19: 767-783. doi: 10.1016/S1474-4422(20)30221-0.

  18. Lodigiani C, Iapichino G, Carenzo L, Cecconi M, Ferrazzi P,Sebastian T, et al. Venous and arterial thromboemboliccomplications in COVID-19 patients admitted to an academichospital in Milan, Italy. Thromb Res 2020; 191: 9-14.doi: 10.1016/j.thromres.2020.04.024.

  19. Gagliardi I, Patella G, Michael A, Serra R, Provenzano M,Andreucci M. COVID-19 and the Kidney: from epidemiologyto clinical practice. J Clin Med 2020; 9: 1-29. doi: 10.3390/jcm9082506.

  20. Naicker S, Yang CW, Hwang SJ, Liu BC, Chen JH, Jha V. TheNovel Coronavirus 2019 Epidemic and Kidneys. KidneyInt 2020; 97 (5): 824-828. doi: https://doi.org/10.1016/j.kint.2020.03.001.

  21. Moitinho MS, Belasco AGS, Barbosa DA, Fonseca CD.Acute kidney injury by SARS-CoV-2 virus in patientswith COVID-19: an integrative review. Rev Bras Enferm2020; 73 (Suppl. 2): e20200354. doi: http://dx.doi.org/10.1590/0034-7167-2020-0354.

  22. Suwanwongse K, Shabarek N. Rhabdomyolysis as a presentationof 2019 novel coronavirus disease. Cureus 2020; 12(4): e7561. DOI: 10.7759/cureus.7561.

  23. Morley JE, Kalantar-Zadeh K, Anker SD. COVID-19: a majorcause of cachexia and sarcopenia? J Cachexia, SarcopeniaMuscle 2020; 11: 863-865. doi: 10.1002/jcsm.12589.

  24. Liao MY, Duan P, Pan ZY, Cai YX, Fan W, Ping AS. Clinicalfeatures and histopathological changes of skeletal musclein patients with COVID-19: Two case reports. ResearchSquare 2020; https://doi.org/10.21203/rs.3.rs-45595/v1.

  25. Wu P, Duan F, Luo C, Liu Q, Qu X, Liang L, Wu K. Characteristicsof ocular findings of patients with coronavirusdisease 2019 (COVID-19) in Hubei Province, China. JAMAOphthalmol 2020; 138 (5): 575-578. doi: 10.1001/jamaophthalmol.2020.1291.

  26. Dockery DM, Rowe SG, Murphy MA, Krzystolik MG. Theocular manifestations and transmission of COVID-19: recommendationsfor preventions. J Emerg Med 2020; 59 (1):137-140. https://doi.org/10.1016/j.jemermed.2020.04.060.

  27. Marazuela M, Giustina A, Puig-Domingo M. Endocrineand metabolic aspects of the COVID-19 pandemic. RevEndocr Metab Disord 2020; 21 (4): 495-507. doi: 10.1007/s11154-020-09569-2.

  28. Pal R, Banerjee M. COVID-19 and the endocrine system:exploring the unexplored. J Endocrinol Invest 2020; 43 (7):1027-1031. https://doi.org/10.1007/s40618-020-01276-8.

  29. Agarwal S, Agarwal SK. Endocrine changes in SARSCoV-2 patients and lessons from SARS-CoV-2. PostgradMed J 2020; 96: 412-416. doi: 10.1136/postgradmedj-2020-137934.

  30. Holshue ML, DeBolt C, Lindquist S, Lofy K, et al. First Caseof 2019 Novel Coronavirus in the United States. N Engl JMed 2020; 382: 929-36. doi: 10.1056/NEJMoa2001191.

  31. Rokkas T. Gastrointestinal involvement in COVID-19: asystematic review and meta-analysis. Ann Gastroenterol2020; 33: 1-11. doi: 10.20524/aog.2020.0506.

  32. Han C, Duan C, Zhang S, Spiegel B, Shi H, Wang W, et al.Digestive symptoms in COVID-19 patients with mild diseaseseverity: clinical presentation, stool viral RNA testing andoutcomes. Am J Gastroenterol 2020; 115 (7): 1003-1006.doi: 10.14309/ajg.0000000000000664.

  33. Wong S, Lui R, Sung J. Covid-19 and the Digestive System. JGastroenterol Hepatol 2020; 35 (5): 744-748. doi: 10.1111/jgh.15047.

  34. Zhang H, Kang ZJ, Gong HY, Xu D, Wang J, Li Z, et al.The digestive system is a potential route of 2019-nCov infection: a bioinformatics analysis based onsingle cell transcriptomes. bioRxiv 2020; doi: https://doi.org/10.1101/2020.01.30.927806.

  35. Jinyang G, Bing H, Jian W. COVID-19: Gastrointestinal manifestationsand potential fecal-oral transmission. Gastroenterology2020; 158: 1518-1519. doi: 10.1053/j.gastro.2020.02.054.

  36. Zhang C, Shi L, Wang FS. Liver injury in COVID-19: managementand challenges. Lancet Gastroenterol Hepatol 2020;https://doi.org/10.1016/S2468-1253(20)30057-1.

  37. Cai Q, Huang D, Yu H, Chen J, Liu L, Xu L, et al. COVID-19:Abnormal liver function tests. J Hepatol 2020; 73 (1): 566-574. doi: 10.1016/j.jhep.2020.04.006.

  38. Alqahtani SA, Schattenberg JM. Liver injury in COVID-19:The current evidence. United European Gastroenterol J2020; 8 (5): 509-519. doi: 10.1177/2050640620924157.

  39. Xu Z, Shi L, Wang Y, Zhang J, et al. Pathological findings ofCOVID-19 associated with acute respiratory distress syndrome.Lancet Respir Med 2020; 8: 420-422. doi: 10.1016/S2213-2600(20)30076-X.

  40. Fan Z, Chen L, Li J, Tian C, et al. Clinical features ofCOVID-19 related liver damage. medRxiv Preprint28 February 2020: 2020.2002. 2026.20026971. DOI:10.1101/2020.02.26.20026971.

  41. Shi Y, Wang Y, Shao C, Huang J, Gan J, Huang X, et al. COVID-19 infection: The perspectives on immune responses.Cell Death Differ 2020; 27: 1451-1454. doi: 10.1038/s41418-020-0530-3.

  42. Recalcati S. Cutaneous manifestations in COVID-19: a firstperspective. J Eur Acad Dermatol Venereol 2020; 34 (5):e212-e213. doi: 10.1111/jdv.16387.

  43. Catalá G, Galván C. COVID-19 y piel. Actas Dermosifilogr2020; 111: 447-449. DOI: 10.1016/j.ad.2020.04.007.

  44. Freeman EE, McMahon DE, Lipoff JB, Rosenbach M, KovarikC, Desai SR, et al. The spectrum of COVID-19 – associateddermatologic manifestations: An international registry of 716patients from 31 countries. J Am Acad Dermatol 2020; 83 (4):1118-1129. https://doi.org/10.1016/j.jaad.2020.06.1016.

  45. Freeman EE, McMahon DE, Lipoff JB, Rosenbach M, KovarikC, Takeshita J, et al. Pernio-like skin lesions associated withCOVID-19: a case series of 318 patients from 8 countries.J Am Acad Dermatol 2020; 83: 486-492. doi: 10.1016/j.jaad.2020.05.109.

  46. Saleem H, Rahman J, Aslam N, Murtazaliev S, Khan S. Coronavirusdisease 2019 (COVID-19) in children: vulnerable orspread? A Systematic Review. Cureus 2020; 12 (5): e8207.DOI 10.7759/cureus.8207.

  47. Lu X, Zhang L, Du H, Zhang J, Li Y, et al. SARS-CoV-2 infectionin children. N Engl J Med 2020; 382 (17): 1663-1664. doi:10.1056/NEJMc2005073.

  48. Morand A, Fabre A, Pinodier P, Boutin A, Vanel N, et al. COVID-19 virus and children: What do we know? Arch Pédiatr2020; 27: 117-118. doi: 10.1016/j.arcped.2020.03.001.

  49. Toubiana J, Poirault C, Corsia A, Bajolle F, Fourgeaud J,Angoulvant F, et al. Kawasaki-like multisystem inflammatorysyndrome in children during the covid-19 pandemicin Paris, France: prospective observational study. BMJ2020; 369: m2094. http://dx.doi.org/10.1136 bmj.m2094.

  50. Feldstein LR, Rose EB, Horwitz SM, Collins JP, NewhamsNM, Son MBF, et al. Multisystem Inflammatory Syndromein U.S. children and adolescents. N Engl J Med 2020; 383:334-346. doi: 10.1056/NEJMoa2021680.

  51. López N, Gonce A, Meler E, Plaza A, Hernández S,Martínez-Portilla RJ, et al. Coronavirus disease 2019 inpregnancy: a clinical management protocol and considerationsfor practice. Fetal Diagn Ther 2020; 47: 519-518.doi: 10.1159/000508487.

  52. Chen H, Guo J, Wang C, Luo F, Yu X, Zhang W, et al. Clinicalcharacteristics and intrauterine vertical transmission potentialof COVID-19 infection in nine pregnant women: aretrospective review of medical records. Lancet 2020; 395:809-815. doi: 10.1016/S0140-6736(20)30360-3.

  53. Ortiz EI, Herrera E, De la Torre A. Coronavirus (COVID-19)infection in pregnancy. Colom Med 2020; 51 (2): 1-8. doi:10.25100/cm.v51i2.4271.




2020     |     www.medigraphic.com